HKU School of Computing and Data Science research team develops ClairS, achieving high-accuracy cancer mutation detection across multiple cancer types

A research team led by Professor Ruibang LUO, Assistant Director (Learning Experience & Student Enrichment) and Associate Head of the Department of AI & Data Science, School of Computing and Data Science (CDS), The University of Hong Kong (HKU), has developed ClairS-a novel deep-learning algorithm that significantly improves the detection of cancer mutations using long-read sequencing. Tested on breast cancer, lung cancer and melanoma cell-line datasets, ClairS has demonstrated exceptional accuracy across various cancer types and sequencing conditions.

Cancer mutations are genetic changes found in tumour cells but not in healthy cells; detecting them accurately is essential for cancer research and precision medicine. However, many existing methods are designed for short-read sequencing and often struggle to analyse structurally complex regions of the human genome. ClairS addresses this challenge by utilising long-read sequencing to reveal mutations that might otherwise be missed.

A key innovation of ClairS lies in its method for obtaining training data and labels. Because high-quality cancer training data is limited, the research team designed a novel strategy that mixes sequencing data from normal human samples to generate synthetic tumour-normal data. This allows ClairS to generate a virtually unlimited number of realistic, cancer-like training examples covering various tumour purities, sequencing depths and mutation levels. The result is a flexible and robust artificial intelligence (AI) model for real-world cancer genomic analysis.

ClairS has been tested on multiple cancer cell lines-including breast, lung, melanoma and pancreatic cancers-demonstrating high accuracy in detecting small cancer mutations. Importantly, ClairS has already been integrated into Oxford Nanopore Technologies' official somatic variant-calling workflow, making it part of a practical commercial analysis pipeline. This marks a major step towards the widespread application of advanced sequencing technologies in clinical genomics.

Professor Luo commented, "Long-read sequencing is transforming how we study cancer genomes, especially in regions that were previously difficult to analyse. ClairS makes it possible to train powerful AI models even when real cancer training data is limited, supporting more reliable cancer mutation discovery from long-read sequencing data."

This study represents a significant step towards more accurate and comprehensive cancer genomic analysis. It also highlights a scalable approach to training medical AI when real clinical data is scarce, laying a solid foundation for the future of long-read clinical genomics.

The research has been published Nature Methods titled "ClairS: a deep-learning method for long-read tumor-normal pair somatic small variant calling". ClairS is open source and available at https://github.com/HKU-BAL/ClairS.
Read the publication: https://www.nature.com/articles/s41592-026-03152-4

About Professor Ruibang LUO
Professor Ruibang LUO is an Associate Professor of the School of Computing and Data Science at the University of Hong Kong. He is also the Assistant Director (Learning Experience & Student Enrichment) and Associate Head of AI & Data Science Division. He completed his PhD training in Bioinformatics with Prof. Tak-Wah LAM at the University of Hong Kong (2010-2015), and his postdoctoral training with Prof. Steven SALZBERG and Prof. Michael SCHATZ at the Center of Computational Biology, Johns Hopkins University (2016-2017).

Professor Luo is a researcher working on bioinformatics algorithms and clinical informatics. He published more than 100 papers, with ten achieving over a thousand citations. He has been identified as Top 1% Scholars Worldwide by Clarivate Analytics since 2019, selected by Baidu Research as Worldwide Top 150 Chinese Young Scholars in AI, named Top 10 Innovators Under 35 Asia Pacific by MIT Technology Review in 2019, and recognised as 30 Under 30 Asia in Healthcare and Science by Forbes in 2017.